GreenwichMD

GreenwichMD WELCOME πŸ™πŸ»
πŸ§˜πŸ»β€β™‚οΈ Your Beauty & Wellness Start Now.
πŸ‘‰πŸ»Inside-out health thro

Powerful peptides working together to boost collagen, improve elasticity, and reveal healthier, more resilient skin ✨Boo...
01/19/2026

Powerful peptides working together to boost collagen, improve elasticity, and reveal healthier, more resilient skin ✨

Book your consultation now β€” click the link in our bio.

When results speak for themselves. πŸ’‰πŸ‘„Book your consultation now β€” click the link in our bio.
01/18/2026

When results speak for themselves. πŸ’‰πŸ‘„

Book your consultation now β€” click the link in our bio.

01/15/2026

I asked the universe for a sign…
and it answered in the clouds β˜οΈπŸ’‰

πŸ“² Book your consultation now β€” click the link in our bio.

2026 energy: strategic treatments, elevated results, timeless beauty.πŸ’¬ Comment below the first three procedures you foun...
01/14/2026

2026 energy: strategic treatments, elevated results, timeless beauty.

πŸ’¬ Comment below the first three procedures you found.

🚨 FDA Approval Milestone in Mitochondrial MedicineThe FDA has approved the first mitochondria-targeted peptide therapy:S...
01/11/2026

🚨 FDA Approval Milestone in Mitochondrial Medicine

The FDA has approved the first mitochondria-targeted peptide therapy:
SS-31 (elamipretide), branded as Forzinity.

In September 2025, the U.S. Food and Drug Administration granted accelerated approval to Forzinity as the first approved treatment for Barth syndrome β€” a rare mitochondrial disorder associated with severe muscle weakness, cardiac complications, and reduced lifespan.

🧬 How it works:
Elamipretide is a synthetic peptide that selectively targets mitochondria by binding to cardiolipin, a critical lipid in the inner mitochondrial membrane. This interaction helps stabilize mitochondrial structure and enhance cellular energy production.

πŸ“Š Approval details:
β€’ Indicated for patients weighing β‰₯ 30 kg
β€’ Approval based on improvements in knee extensor muscle strength
β€’ A post-approval confirmatory trial is required to verify clinical benefit

πŸ”¬ While currently approved for Barth syndrome, elamipretide’s mitochondrial mechanism has positioned it at the center of ongoing research into mitochondrial dysfunction and bioenergetics.

✨ A significant step forward in precision peptide therapy.

Source: U.S. Food and Drug Administration (FDA) β€” Accelerated Approval of Forzinity (elamipretide), September 2025.

You lost the weight β€” now restore your skin, strength, and confidence with our GLP-1 Confidence Program. ✨Book your cons...
01/10/2026

You lost the weight β€” now restore your skin, strength, and confidence with our GLP-1 Confidence Program. ✨

Book your consultation now β€” click the link in our bio.

Address

40 East Putnam Avenue, Suite 2D
Cos Cob, CT
06807

Opening Hours

Monday 10am - 6pm
Tuesday 10am - 6pm
Wednesday 10am - 6pm
Thursday 10am - 6pm
Friday 10am - 6pm
Saturday 10am - 12:15am

Telephone

+12035425606

Alerts

Be the first to know and let us send you an email when GreenwichMD posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to GreenwichMD:

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram